---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000027"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:02:44.274076+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026

## Summary
- Lilly elected to terminate the License and Collaboration Agreement for ocadusertib on April 16, 2026; effective June 15, 2026.
- Rigel will regain full rights to ocadusertib and associated RIPK1 inhibitors after termination.
- CNS disease program under the agreement was already terminated effective November 2025.
- Rigel does not expect to receive any future milestones or royalties under the terminated agreement.
- Rigel is evaluating the impact; no financial guidance or changes provided.

## SEC filing metadata
- accession: 0001034842-26-000027
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/0001034842-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/rigl-20260416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000027
- JSON: https://secwatch.observer/filing/0001034842-26-000027.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000027.txt

## Source-grounded claims
- claim_id: f1f2931d60c814335aded9d7b4e54839510c57ef
  claim: RIGEL PHARMACEUTICALS INC terminated License and Collaboration Agreement with Eli Lilly and Company valued at Lilly's election to terminate the License and Collaboration Agreement in its entirety; Rigel expects (effective 2026-06-15).
  evidence_excerpt: On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/0001034842-26-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.